Study identifier:D0510C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2007-003474-26
CTIS identifier:N/A
A Phase I, Single-Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 after Single Ascending Doses in Healthy Male Volunteers
Healthy
Phase 1
Yes
AZD3043
Male
53
Interventional
18 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This is a Phase I, single centre, open label study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of intravenous AZD3043 after single ascending doses in healthy male volunteers.
Location
Location
Stockholm, Sweden
Arms | Assigned Interventions |
---|---|
Experimental: AZD3043 Intravenous solution | Drug: AZD3043 intravenous solution given once as intravenous infusion over 30 minutes |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.